{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:02:46Z","timestamp":1781024566869,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100938","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:34:40Z","timestamp":1774373680000},"page":"100938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"Florian","family":"Lordick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Barzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.100938_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.36","article-title":"Gastric adenocarcinoma","volume":"3","author":"Ajani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.gastha.2026.100938_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.gastha.2026.100938_bib7","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib8","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.gastha.2026.100938_bib9","doi-asserted-by":"crossref","first-page":"S1526","DOI":"10.1016\/j.annonc.2023.10.274","article-title":"139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC): final analysis results of the RATIONALE-305 study","volume":"34","author":"Xu","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib10","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2026.100938_bib12","author":"Schroeder"},{"key":"10.1016\/j.gastha.2026.100938_bib13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.gastha.2026.100938_bib15","author":"Lordick"},{"key":"10.1016\/j.gastha.2026.100938_bib19","author":"Kim"},{"key":"10.1016\/j.gastha.2026.100938_bib21","author":"Rosa"},{"key":"10.1016\/j.gastha.2026.100938_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.908026","article-title":"A meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer","volume":"12","author":"El Helali","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1781333","article-title":"A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy","volume":"9","author":"Peng","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gastha.2026.100938_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000531457","article-title":"Efficacy of PD-1 inhibitors in first-line treatment for advanced gastroesophageal junction and gastric cancer by subgroups: a systematic review and meta-analysis","volume":"68","author":"Fei","year":"2023","journal-title":"Chemotherapy"},{"key":"10.1016\/j.gastha.2026.100938_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/imt-2022-0305","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis","volume":"15","author":"Liu","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastha.2026.100938_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7080","article-title":"East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: an updated meta-analysis","volume":"13","author":"Yao","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.gastha.2026.100938_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00432-018-02828-5","article-title":"Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations","volume":"145","author":"Zhang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib31","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.100938_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/JCO.2025.43.4_suppl.370","article-title":"Patterns of immune checkpoint inhibitor utilization and PD-L1 testing in advanced gastroesophageal cancers using real-world data","volume":"43","author":"Kaur","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib33","author":"Higgins"},{"key":"10.1016\/j.gastha.2026.100938_bib35","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2026.100938_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 Guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.gastha.2026.100938_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2026.100938_bib40","series-title":"Summing up: the science of reviewing research","author":"Light","year":"1984"},{"key":"10.1016\/j.gastha.2026.100938_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.gastha.2026.100938_bib42","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2026.100938_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.4_suppl.304","article-title":"Comparison of survival between de novo stage IV and recurrent stage IV gastric cancer","volume":"41","author":"Ji","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2024.42.3_suppl.282","article-title":"De novo metastatic versus recurrent gastroesophageal cancer: a single-centre retrospective analysis","volume":"42","author":"Farooq","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastha.2026.100938_bib46","article-title":"PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: a network meta-analysis","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2026.100938_bib48","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ijc.34427","article-title":"The regulatory approvals of immune checkpoint inhibitors in China and the United States: a cross-national comparison study","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gastha.2026.100938_bib49","article-title":"Oncological outcomes of addition of anti-PD1\/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: a meta-analysis","volume":"99","author":"Zheng","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:49:54Z","timestamp":1781023794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000592"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100938","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100938"}}